Abeona Therapeutics Inc. (NASDAQ:ABEO) went down by -5.83% from its latest closing price compared to the recent 1-year high of $4.07. The company’s stock price has collected -22.79% of loss in the last five trading sessions. Press Release reported on 02/22/21 that Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Is It Worth Investing in Abeona Therapeutics Inc. (NASDAQ :ABEO) Right Now?
Plus, the 36-month beta value for ABEO is at 1.60. Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for Abeona Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $5.67. ABEO currently public float of 84.39M and currently shorts hold a 3.41% ratio of that float. Today, the average trading volume of ABEO was 3.76M shares.
ABEO’s Market Performance
ABEO stocks went down by -22.79% for the week, with a monthly drop of -0.94% and a quarterly performance of 56.72%, while its annual performance rate touched -46.29%. The volatility ratio for the week stands at 14.43% while the volatility levels for the past 30 days are set at 14.51% for Abeona Therapeutics Inc.. The simple moving average for the period of the last 20 days is -17.19% for ABEO stocks with a simple moving average of -4.60% for the last 200 days.
Analysts’ Opinion of ABEO
Many brokerage firms have already submitted their reports for ABEO stocks, with Cantor Fitzgerald repeating the rating for ABEO by listing it as a “Overweight.” The predicted price for ABEO in the upcoming period, according to Cantor Fitzgerald is $4 based on the research report published on November 11th of the previous year 2020.
B. Riley FBR, on the other hand, stated in their research note that they expect to see ABEO reach a price target of $5. The rating they have provided for ABEO stocks is “Buy” according to the report published on September 18th, 2020.
SVB Leerink gave a rating of “Outperform” to ABEO, setting the target price at $6 in the report published on February 10th of the previous year.
ABEO Trading at 2.47% from the 50-Day Moving Average
After a stumble in the market that brought ABEO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.40% of loss for the given period.
Volatility was left at 14.51%, however, over the last 30 days, the volatility rate increased by 14.43%, as shares sank -9.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +43.84% upper at present.
During the last 5 trading sessions, ABEO fell by -22.79%, which changed the moving average for the period of 200-days by -9.87% in comparison to the 20-day moving average, which settled at $2.52. In addition, Abeona Therapeutics Inc. saw 33.76% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at ABEO starting from Wider Todd, who sale 251,625 shares at the price of $2.39 back on Feb 19. After this action, Wider Todd now owns 25,000 shares of Abeona Therapeutics Inc., valued at $601,057 using the latest closing price.
Mann Paul Elliot, the Director of Abeona Therapeutics Inc., sale 45,566 shares at $2.38 during a trade that took place back on Feb 19, which means that Mann Paul Elliot is holding 0 shares at $108,502 based on the most recent closing price.
Stock Fundamentals for ABEO
The total capital return value is set at -48.12, while invested capital returns managed to touch -47.87. Equity return is now at value -62.00, with -47.00 for asset returns.
Based on Abeona Therapeutics Inc. (ABEO), the company’s capital structure generated 4.46 points at debt to equity in total, while total debt to capital is 4.27. Total debt to assets is 3.56, with long-term debt to equity ratio resting at 3.50. Finally, the long-term debt to capital ratio is 3.35.
The liquidity ratio also appears to be rather interesting for investors as it stands at 3.42.